Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2138 plus chemotherapy with pembrolizumab versus placebo plus chemotherapy with or without pembrolizumab for first-line HER2-negative, CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma
jRCT2031260234Phase 3Recruiting
- Sponsor
- Astellas Pharma
- Start
- Jul 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing ASP2138 plus chemotherapy and pembrolizumab with Placebo plus chemotherapy with or without pembrolizumab (2 arms). Primary endpoints: Overall survival and Progression-free survival by blinded independent central review. Started Jul 2026; status: recruiting.
02
Drugs
ASP2138
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031260234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260234.